The Journal of asthma : official journal of the Association for the Care of Asthma · 2008
Do different vaccination regimens for BCG and hepatitis B affect the development of allergic disorders in early childhood?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dilli Dilek, Bostanci Ilknur, Dallar Yildiz
Аннотация
AIM: To determine whether age at bacilli Calmette-Guérin (BCG) and hepatitis B vaccination has an effect on the development of atopy and allergic disorders in early childhood.
METHODS: This was a cross-sectional study of 109 children aged between 24 and 36 months with respiratory system diseases. The study population was divided into two groups according to vaccination regimens: group 1, beginning hepatitis B vaccination at birth and receiving BCG vaccine at two months of age; group 2, receiving BCG vaccine at birth and beginning hepatitis B vaccination at two months of age. Atopic status was assessed by skin-prick tests (SPTs).
RESULTS: There was no statistically significant difference in atopy between two groups (p = 0.27). However, the prevalence of recurrent wheezing was higher in group 1 (36.4%) than group 2 (16.3%) (p = 0.04). Logistic regression analysis identified receiving BCG vaccine at birth and beginning hepatitis B vaccination at the age of two months were protective for recurrent wheezing (odds ratio 0.5; confidence interval: 0.3-0.8; p = 0.01).
CONCLUSION: We believe that the administration of BCG vaccine at birth and hepatitis B vaccine at two months may be protective against recurrent wheezing but doesn't prevent atopy.
METHODS: This was a cross-sectional study of 109 children aged between 24 and 36 months with respiratory system diseases. The study population was divided into two groups according to vaccination regimens: group 1, beginning hepatitis B vaccination at birth and receiving BCG vaccine at two months of age; group 2, receiving BCG vaccine at birth and beginning hepatitis B vaccination at two months of age. Atopic status was assessed by skin-prick tests (SPTs).
RESULTS: There was no statistically significant difference in atopy between two groups (p = 0.27). However, the prevalence of recurrent wheezing was higher in group 1 (36.4%) than group 2 (16.3%) (p = 0.04). Logistic regression analysis identified receiving BCG vaccine at birth and beginning hepatitis B vaccination at the age of two months were protective for recurrent wheezing (odds ratio 0.5; confidence interval: 0.3-0.8; p = 0.01).
CONCLUSION: We believe that the administration of BCG vaccine at birth and hepatitis B vaccine at two months may be protective against recurrent wheezing but doesn't prevent atopy.